IMUX - IMMUNIC, INC.

0.895
-0.048   -5.385%

Share volume: 802,501
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.94
-0.05
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 0%
Dept financing 8%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-10.05%
1 Month
-17.89%
3 Months
-14.76%
6 Months
-40.33%
1 Year
-30.62%
2 Year
-32.71%
Key data
Stock price
$0.90
P/E Ratio 
0.00
DAY RANGE
$0.88 - $1.04
EPS 
-$1.65
52 WEEK RANGE
$0.88 - $2.11
52 WEEK CHANGE
-$35.61
MARKET CAP 
148.630 M
YIELD 
N/A
SHARES OUTSTANDING 
90.079 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
1.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$819,318
AVERAGE 30 VOLUME 
$646,276
Company detail
CEO: Daniel Vitt
Region: US
Website: immunic-therapeutics.com
Employees: 70
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

Recent news
loading